Alex Ehsan: Antiphospholipid Syndrome – A Practical Guide
Alex Ehsan, Hematologist and Medical Oncologist at Starling Oncology, shared a post on X:
”Antiphospholipid Syndrome (APS)
APS is an autoimmune clotting disorder that can cause DVT, PE, stroke, cerebral venous sinus thrombosis, arterial thrombosis and pregnancy complications.
Test the complete APS panel
- Lupus anticoagulant with dRVVT and confirmatory testing
- Anticardiolipin IgG and IgM
- β2 glycoprotein I IgG and IgM
A positive result should be confirmed at least 12 weeks later to establish persistence.
Anticoagulants can interfere particularly with lupus anticoagulant testing.
For confirmed thrombotic APS, warfarin is generally preferred, usually INR 2 to 3 for venous thrombosis.
Warfarin is particularly important with triple positive APS, arterial thrombosis or recurrent thrombosis.
DOACs should generally be avoided in triple positive or arterial APS.
They may be considered selectively in lower risk venous APS when warfarin cannot reasonably be used.
A positive antibody alone does not equal APS.
The clinical thrombotic history plus persistent antibody profile determine the diagnosis and treatment.
Educational only.”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian